On December 17, 2020, according to the Xinhua News Agency, the State Council announced that five China-produced COVID-19 vaccines have been in phase III clinical trials, and preparations are being made for large-scale production under the premise of ensuring safety and effectiveness.
Major Subjects of Public Concern
Per the news staff, here are some key subjects before people getting vaccinated against COVID-19.
Price of Vaccine-200 Yuan/dose
On December 15, 2020, Jiangsu Public Resource Trading Platform announced on its official platform that the purchase price of vaccine was 200 yuan per dose, which will be used for emergency use across the province.
According to the CDC of Jiaxing City, as of now, people shall get vaccinated twice, with an interval of 2-4 weeks. Therefore, with the service charge for vaccination, it will cost about 456 yuan for the vaccination.
Rates of Prevention of Vaccine against COVID-19 - Around 86%
As per the Xinhua News Agency, the current analysis shows that the effective rate of COVID-19 inactivated vaccine developed by SINOPHARM is 86%, and has 99% neutralization antibody serum conversion rate, and 100% effectiveness in preventing mild-disease of COVID-19 from transforming into moderate and severe disease, as well as no serious safety risks.
Period of Validity - One to Three Years
Per Zhou Song, general counsel of SINOPHARM, the durability of immunization, and the effect of protection are estimated to be more than 1 to 3 years. Continuous observation of the protection of the COVID-19 vaccine is still ongoing.
Side Effects - Mild Adverse Reactions
On October 20, 2020, according to Tian Baoguo, deputy director of the Ministry of Science and Technology, only mild adverse reactions were seen after people receiving the China-produced COVID-19 vaccine, including local pain and discomfort, redness and swelling, as well as slight fever and fever. However, the five vaccines that have entered the phase III clinical trial are all basically mild adverse reactions, with no serious adverse effects being reported.
COVID-19 Vaccination Program for Public in 6 Big Cities
According to the Kunming Health Committee, the vaccine developed by SINOPHARM is expected to be launched in late December and will be introduced into Kunming after approval ASAP.
As a result, the OT-Team also consulted the relevant departments of the following six cities, including Beijing, Shanghai, Shenzhen, Hangzhou, Chengdu, and Suzhou, on local vaccination arrangements for the public. Below are the official responses.
Vaccination Program in Beijing
Up to now, the public vaccination schedule hasn’t been released by the Beijing Municipal Government. But per the working staff, if there is an urgent need for some personnel, it is recommended to call the CDC at 010-64212461;
Vaccination Program in Shanghai
Per the working staff, there is no update on vaccination-related information recently;
Vaccination Program in Shenzhen
As per the staff of Shenzhen Municipal Government, foreign-related enterprises in Shenzhen can apply to the local commerce bureau or foreign affairs office for vaccination; however, it is not yet open to the public to make an appointment for vaccination;
Vaccination Program in Hangzhou
Until now, there has not been any notification of public vaccination, the working staff said;
Vaccination Program in Chengdu
Per the working staff, residents who are willing to get vaccinated against COVID-19 can apply to the local community health service center;
Vaccination Program in Suzhou
As per the staff, the specific information about the COVID-19 vaccination schedule will be released after the vaccine is officially launched.
According to the State Council, at present, local governments will formulate vaccination distribution plans after the vaccine goes on the market, clarifying the population size, vaccination sequence, and timing.